Профилактика рецидивов хронического кандидозного вульвовагинита у женщин в период ранней постменопаузы

В. А. Бенюк; Л. Д. Ластовецкая; Е. А. Щерба

doi:10.18370/2309-4117.2015.23.34-40

Authors

В. А. Бенюк National Medical University named after A.A. Bogomolets, Ukraine
Л. Д. Ластовецкая National Medical University named after O.O. Bogomolets, Ukraine
Е. А. Щерба National Medical University named after O.O. Bogomolets, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.23.34-40

Keywords:

chronic recurrent vulvovaginal candidiasis, anti-inflammatory medication, Livarol, early postmenopause

Abstract

The effectiveness of the proposed treatment of chronic recurrent vulvovaginal candidiasis in women in the early postmenopausal period compared to standard methods.

The main group of women included in the study consisted of 20 patients with chronic recurrent vulvovaginal candidiasis who received antifungal therapy with Livarol and immunomodulator Lavomax. The second group included 18 patients with chronic recurrent vulvovaginal candidiasis who received therapy with anti-mycotic Livarol. The control group consisted of 20 healthy women.

It has been shown that the use in combined therapy with anti-inflammatory improves the clinical manifestation of the disease, accelerates the healing process, reduces insemination of genital tract by pathological flora.

Author Biographies

В. А. Бенюк, National Medical University named after A.A. Bogomolets

MD, Professor, Head

Obstetrics and Gynecology Department number 3

Л. Д. Ластовецкая, National Medical University named after O.O. Bogomolets

PhD, associate professor of the Obstetrics and Gynecology Department number 3

Е. А. Щерба, National Medical University named after O.O. Bogomolets

Assistant of the Obstetrics and Gynecology Department number 3

References

Beniuk, V.O., Shcherba, O.A., Lastovetska, L.D. “Criteria for evaluating the effectiveness of treatment of vulvovaginitis caused by Candida-associated herpes infection.” Taurian Medical and Biology Gazette, 3(55) (1) (2011): 27–31.
Mayorov, M.V. “Actual issues of the treatment of vaginal candidiasis.” Medical Aspects of Women's Health, 4(31) (2010): 54–62.
Medyannikova, I.V. “The effectiveness of immunotherapy with Lavomax at colpitis and cervicitis.” Obstetrics and Gynecology, 6(2007): 55–58.
United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (Clinical Effectiveness Group British Association of Sexual Health and HIV). Medical Aspects of Women's Health, 4(21) (2009): 21–30.
Radzinskyi, V.E., Ordiyants, I.M., Chetvertakova, E.S., Misunov, O.A. “Two-stage treatment of vaginal infections.” Obstetrics and Gynecology, 5(2011): 1–4.
Reznichenko, N.A. “Clinical and pathogenetic significance of hormonal systems and their correction with infertility on the background of genital mixed candidiasis in women.” Health of Ukraine, 3(7) (2012): 34.
Roshchyna, G.F. “Current approaches to management patients with urogenital disorders during menopause.” Women's Health, 2(30) (2007): 127–134.
Tatarchuk, T.F., Solskyi, Y.P. Endocrine Gynecology. K. (2003): Part 1.
Tikhomirov, A.L., Oleynik, Ch.G. “Pathophysiology of menopause and new opportunities of hormone replacement therapy in postmenopausal women.” Russian Journal of Medicine, 16 (Vol. 1) (2003): 13–17.
C hu, C.T., Oury, T.D., Enghild, J.J., Pizzo, S.V. J Immunol, 152(1994): 1538–1545.
Hay, F.Bacteralvaginosis Mеdicine, 10(33) (2005): 58–61.
M oehrer, B., Hertal, A., Jackson S. “Oestrogens for urinary incontinence in women.” Cochrane Database Syst Rev, 2(2003): CD001405.